Toxicity rate associated with infusing donor CD8+ CTL clones specific for WT1 in patients at high risk for post transplant relapse of CML, AML, or ALL Up to 4 weeks after the final dose of CTL [clinicaltrials_resource:e8685623c322118d61ef395ee78372ee]
Assessed by Common Terminology Criteria (CTC) version 3.0.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Toxicity rate associated with infusing donor CD8+ CTL clones specific for WT1 in patients at high risk for post transplant relapse of CML, AML, or ALL Up to 4 weeks after the final dose of CTL [clinicaltrials_resource:e8685623c322118d61ef395ee78372ee]
Assessed by Common Terminology Criteria (CTC) version 3.0.
Bio2RDF identifier
e8685623c322118d61ef395ee78372ee
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:e8685623c322118d61ef395ee78372ee
measure [clinicaltrials_vocabulary:measure]
Toxicity rate associated with ...... nt relapse of CML, AML, or ALL
time frame [clinicaltrials_vocabulary:time-frame]
Up to 4 weeks after the final dose of CTL
description
Assessed by Common Terminology Criteria (CTC) version 3.0.
identifier
clinicaltrials_resource:e8685623c322118d61ef395ee78372ee
title
Toxicity rate associated with ...... ks after the final dose of CTL
@en
type
label
Toxicity rate associated with ...... 85623c322118d61ef395ee78372ee]
@en